HBeAg negative patients

Related by string. * : HBeAg seroconversion . HBeAg negative chronic hepatitis . HBeAg positive patients . HBeAg negative / Negatives . negatives . NEGATIVE . NEGATIVES : Rating Watch Negative . Negative Rating Outlook . Negative Outlook reflects . estrogen receptor negative / PATIENTS . PATIENT . pa tients : Breast Cancer Patients . terminally ill patients . Patient Safety * *

Related by context. Frequent words. (Click for all words.) 73 chlorambucil 69 plus dexamethasone 69 patients evaluable 69 mycophenolate mofetil 69 plus methotrexate 69 % CI #.#-#.# [007] 68 mg kg dose 68 peginterferon alfa 2b 68 mg QD 68 virologic failure 67 active comparator 67 confidence interval #.#-#.# 67 irbesartan 67 achieved statistical significance 66 peginterferon alfa 2a 66 leukopenia 66 lymphopenia 66 μg kg 66 Arch Intern Med 66 coinfected 66 DOXIL 66 % CI #.#-#.# [006] 66 Chronic Hepatitis C 66 Fludara 66 tocilizumab 66 STELARA 66 plus prednisone 65 adefovir 65 azacitidine 65 decitabine 65 linezolid 65 relapsed multiple myeloma 65 heavily pretreated 65 P = .# 65 adalimumab 65 CI #.#-#.# [002] 65 febrile neutropenia 64 placebo controlled clinical trials 64 HBV DNA 64 tolvaptan 64 ACR# response 64 lamivudine 64 acute coronary syndromes ACS 64 lamotrigine 64 events AEs 64 tamsulosin 64 angiotensin converting enzyme inhibitors 64 placebo p = 64 PegIntron 64 mg BID 64 cabazitaxel 64 Navelbine 64 virologic response 64 hypokalemia 64 tipranavir 64 mcg dose 64 evaluable 64 cytogenetic response 64 amphotericin B 64 plus gemcitabine 64 relapsed refractory multiple myeloma 64 laboratory abnormalities 64 raltegravir 64 glatiramer acetate 64 fluorouracil 63 sustained virologic response 63 interferon alfa 63 Secondary endpoints included 63 enalapril 63 anakinra 63 nonresponders 63 CI -#.# 63 REMICADE ® 63 elotuzumab 63 enfuvirtide 63 Secondary endpoints 63 FOLFOX 63 annualized relapse 63 azathioprine 63 entecavir 63 darunavir 63 VICTRELIS 63 peginterferon 63 darbepoetin alfa 63 LEXIVA 63 Ann Intern Med 63 TNF antagonists 63 metastatic renal cell carcinoma 63 nasopharyngitis 63 confidence interval CI 63 diabetic neuropathic pain 63 neoadjuvant 63 Pivotal Phase III 63 nitazoxanide 62 placebo controlled clinical 62 Taxotere ® 62 infliximab 62 glimepiride 62 bosentan 62 XELOX 62 PEG INTRON

Back to home page